Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023 Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced certain […]

Investors with deep pockets seek refuge in GDP Capital’s PE-BOND Fund amidst turbulent markets Key Investment Sectors KUALA LUMPUR, Malaysia, Jan. 09, 2024 (GLOBE NEWSWIRE) — The COVID-19 pandemic has unleashed unprecedented economic turmoil, resulting in contracting markets and dwindling returns worldwide. Private Equity and other investment sectors find themselves navigating an exceptionally challenging and […]

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from […]

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from […]

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from […]